Table 1

Patient and tumor characteristics for the entire cohort and by patient age group

CharacteristicsEntire cohort
(801 patients)
n (%)
Younger elderly
(627 patients)
n (%)
Older elderly
(174 patients)
n (%)
P value
Age, years (median, range)69 (65–90)68 (65–74)77 (75–90)
Tumor size, cm4.5±2.14.4±2.14.7±2.10.13
Histology
 Endometrioid573 (71.5)458 (73.0)115 (66.1)0.09
 Non-endometrioid228 (28.5)169 (27.0)59 (33.9)
Grade
 1183 (22.8)150 (24.0)33 (19.0)0.04
 2272 (34.0)221 (35.2)51 (29.3)
 3346 (43.2)256 (40.8)90 (51.7)
LVSI
 Positive346 (43.2)272 (43.4)74 (42.5)0.13
 Negative344 (42.9)276 (44.0)68 (39.1)
 Unknown111 (13.9)79 (12.6)32 (18.4)
Myometrial invasion
 None35 (4.4)29 (4.6)6 (3.4)0.83
 <1/2259 (32.3)204 (32.5)55 (31.7)
 ≥1/2507 (63.3)394 (62.9)113 (64.9)
Glandular invasion
 Positive126 (15.7)88 (14.0)38 (21.8)0.03
 Negative614 (76.7)492 (78.5)122 (70.1)
 Unknown61 (7.6)47 (7.5)14 (8.1)
Stromal invasion
 Positive235 (29.3)175 (27.9)60 (34.5)0.04
 Negative566 (70.7)452 (72.1)114 (65.5)
Stage
 IA179 (22.3)146 (23.4)33 (19.0)0.87
 IB275 (34.3)212 (33.8)63 (36.2)
 II118 (14.8)91 (14.5)27 (15.5)
 IIIA38 (4.7)29 (4.7)9 (5.2)
 IIIB3 (0.4)3 (0.5)0
 IIIC1105 (13.1)81 (12.9)24 (13.8)
 IIIC283 (10.4)65 (10.4)18 (10.3)
Lymph node dissection
 None67 (8.4)47 (7.5)20 (11.5)0.2
 Pelvic LND227 (28.3)176 (28.1)51 (29.3)
 Pelvic+PA LND507 (63.3)404 (64.4)203 (59.2)
Radiotherapy
 BRT362 (45.2)284 (45.3)78 (44.8)0.92
 ERT145 (18.1)113 (18.0)32 (18.4)
 ERT+BRT294 (36.7)230 (36.7)64 (36.8)
Chemotherapy
 None597 (74.5)463 (73.8)134 (77.0)0.2
 Sequential124 (15.5)99 (15.8)25 (14.4)
 Sandwich80 (10.0)65 (10.4)15 (8.6)
  • BRT, brachytherapy; ERT, external radiotherapy; LND, lymph node dissection; LVSI, lymphovascular space invasion; PA, para-aortic.